SOSUA BAY, Dominican Republic, Sept. 29, 2010 (GLOBE NEWSWIRE) -- Proton Laboratories, Inc. (Pink Sheets:PLBI - News) CEO, Armando Casciati, announced today that Dr. Lee has returned from training with RNL Bio Ltd. in Korea and stated, "The feedback we received from the training in South Korea was extremely positive and continues to reinforce our belief in the process of utilizing adult stem cells to reinvigorate the body and allow it to heal itself. Both Dr. Lee and his assistant had the opportunity to observe, document and study in detail the work being done by RNL directly and also saw U.S. cancer patients who had flown to Korea to be treated." RNL indicated it has had a number of potential patients contact them from the U.S.; however, the difficulty of such a long flight prevented them from going.
In addition, the clean lab modular system installation will commence on October 7th or 8th and is anticipated to take 3-4 weeks.
About Proton Laboratories, Inc. and its wholly owned subsidiary RegenoBody S.A:
RegenoBody S.A., a wholly owned subsidiary of Proton Laboratories, Inc., brings the benefits of bioscience to patients who have been diagnosed with chronic debilitating diseases, offering viable, efficient therapeutic options with special Stem Cell Therapies utilizing the most effective cell regeneration techniques. Therapies are tailored for each individual, based upon their specific needs. Cells are obtained by the most modern technological methods. The transplant physicians and stem cell laboratory scientists associated with RNL Bio have been regarded as some of the best in the world. Stem cells derived from Autologous (Stem cells taken from your own body) and Allogeneic (Stem cells from a source other than your own) are used depending on the particular condition that needs to be treated. Treatments will be delivered by an experienced team of International and U.S. Board Certified Physicians who are guided by strict protocols ensuring excellence in medical care.
About RNL Bio Company LTD:
RNL Bio is a premier biopharmaceutical company focused on development and commercialization of adult stem cell therapeutics and dog cloning technology. Headquartered in Seoul with a state-of-the-art GMP facility, RNL is a publicly traded company on the Korea Exchange (Code 003190) and strives to become a global leader across the biomedical industry.
FORWARD-LOOKING STATEMENT:
This report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this report are made as of the date hereof and the company undertakes no obligation to update such statements.
Wednesday, September 29, 2010
mBeach Software Inc. Focusing on End Results and Goal Achievements of First, Post Merger Milestone
TEL AVIV, Israel, Sept. 29, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News), in accordance with company policy which recognizes the importance of regular communication and timely information delivered to investors, is committed to sharing with our stockholders regular updates on progress.
We have reached our first, post merger milestone and have assessed our goal achievements for the past four months.
mBeach's goals for the first milestone included redefining the activities of mBeach and Skin Cancer Scanning Ltd., instigating initial international marketing activities, progressing in the development of SkinScan 650, and strengthening and increasing shareholder value.
Redefining the core competence activities -- SCS is now focused on its core competencies of research and development, regulatory issues, and conducting further clinical trials in Israel. MBHS is focused on worldwide business and marketing activities. This restructuring will maximize companies' synergies.
Marketing activities -- mBeach has recently signed an MOU with a Russian company for initiating marketing activities in Russia and the Commonwealth of Independent States (CIS). We have identified the Japanese, Hi-Tech orientated market as a potential pivotal market, with increasing awareness to skin cancer related issues. We are now operating to initiate marketing steps into this market.
The U.S. market has been, since inception, the major target market and all development has been conducted in light of DFA and Reimbursement programs' requirements.
We expect these combined activities will increase and create stronger, long term, shareholder value.
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
We have reached our first, post merger milestone and have assessed our goal achievements for the past four months.
mBeach's goals for the first milestone included redefining the activities of mBeach and Skin Cancer Scanning Ltd., instigating initial international marketing activities, progressing in the development of SkinScan 650, and strengthening and increasing shareholder value.
Redefining the core competence activities -- SCS is now focused on its core competencies of research and development, regulatory issues, and conducting further clinical trials in Israel. MBHS is focused on worldwide business and marketing activities. This restructuring will maximize companies' synergies.
Marketing activities -- mBeach has recently signed an MOU with a Russian company for initiating marketing activities in Russia and the Commonwealth of Independent States (CIS). We have identified the Japanese, Hi-Tech orientated market as a potential pivotal market, with increasing awareness to skin cancer related issues. We are now operating to initiate marketing steps into this market.
The U.S. market has been, since inception, the major target market and all development has been conducted in light of DFA and Reimbursement programs' requirements.
We expect these combined activities will increase and create stronger, long term, shareholder value.
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development and commercialization of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Assured Pharmacy Engages UHY, LLP As Auditors
FRISCO, Texas, Sept. 29 /PRNewswire/ -- Assured Pharmacy (Pink Sheets:APHY.pk - News), a pharmacy service healthcare organization operating a chain of specialty pharmacies providing advanced prescription medication fulfillment solutions to sufferers of chronic pain, is pleased to announce that it has retained UHY, LLP ("UHY") to serve as the Company's independent auditors. The decision to engage UHY was based on the Company's preference for a PCAOB accounting firm with national recognition and a strong regional presence that also has significant experience working with emerging growth companies.
"We are pleased to have engaged UHY as our independent auditors," said Robert DelVecchio, CEO of Assured Pharmacy. "We are working diligently towards having UHY complete an audit of our financial statements for the fiscal years ended December 31, 2009 and 2008. Going forward, our intention is to release our financial statements on a timely basis and have our annual financial statements audited. These actions are part of our plan to provide timely and accurate disclosure to our stockholders and further increase the transparency of our operations."
About Assured Pharmacy
Assured Pharmacy, Inc. is a growing chain of specialty pharmacies that provide advanced prescription services to a diverse array of medical professionals and their patients. Assured Pharmacy is committed to providing these physicians and patients with a better prescription process through four community locations. This enhanced process is achieved by blending our specialized service model with focused pharmacology. Our business model targets physicians specializing in pain management – anesthesiology, orthopedics, neurology, oncology, psychiatry, physical rehabilitation and industrial medicine. The focus is on treating patients with long-term, acute, chronic pain conditions.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: the Company's ability to increase revenue and profits in the current economic climate; the effect of changing economic conditions; lack of sufficient financing for opening new pharmacies; inability to manage growth; and changes in government regulations, controls and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company's disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
"We are pleased to have engaged UHY as our independent auditors," said Robert DelVecchio, CEO of Assured Pharmacy. "We are working diligently towards having UHY complete an audit of our financial statements for the fiscal years ended December 31, 2009 and 2008. Going forward, our intention is to release our financial statements on a timely basis and have our annual financial statements audited. These actions are part of our plan to provide timely and accurate disclosure to our stockholders and further increase the transparency of our operations."
About Assured Pharmacy
Assured Pharmacy, Inc. is a growing chain of specialty pharmacies that provide advanced prescription services to a diverse array of medical professionals and their patients. Assured Pharmacy is committed to providing these physicians and patients with a better prescription process through four community locations. This enhanced process is achieved by blending our specialized service model with focused pharmacology. Our business model targets physicians specializing in pain management – anesthesiology, orthopedics, neurology, oncology, psychiatry, physical rehabilitation and industrial medicine. The focus is on treating patients with long-term, acute, chronic pain conditions.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: the Company's ability to increase revenue and profits in the current economic climate; the effect of changing economic conditions; lack of sufficient financing for opening new pharmacies; inability to manage growth; and changes in government regulations, controls and similar matters. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company's disclosures. The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
Tuesday, September 28, 2010
Kalahari Greentech, Inc. Commences Testing of Wind Generator's Turbine Blades
BALTIMORE, Sept. 28, 2010 (GLOBE NEWSWIRE) -- Kalahari Greentech, Inc. (Pink Sheets:KHGT - News) released a statement today that company representatives have begun testing the Wind Generator's turbine blades. The test objectives will measure the total lift force generated by the airflow velocities, as well as the various angles of attack at various temperatures and relative humidity.
The data collected will be used to refine the configuration in the internal chambers of the wind generator, thus making the unit as effective and efficient as possible.
Wind and solar are fast becoming the leading sources of renewable energy, which puts Kalahari Greentech in the right place at the right time. Kalahari Greentech designs, produces and provides wind turbines, solar collectors and other sustainable energy technologies. Nearly $2 billion in money from the American Recovery and Reinvestment Act has been spent on wind power, funding the creation of enough new wind farms to power 2.4 million homes over the past year. (Source: www.abcnews.com).
In a Bloomberg Business Week article, General Electric Co. said it expects global industry-wide sales for land-based wind turbines to grow by $130 billion in the next two years. (Source: http://www.businessweek.com/news/2010-03-02/ge-sees-130-bln-jump-in-land-turbine-sales-by-2012-update1-.html).
Kalahari's Wind Generator concentrates wind energy in a manner such that it can generate electric power at speeds usually too slow for conventional wind generators to produce any meaningful energy, or to even operate. It can also be modified to operate in water. For instance, it can be utilized in streams, rivers and tidal basins.
More information can be found on the company's website, www.kalaharigt.com.
About Kalahari Greentech, Inc.: Kalahari Greentech Inc. is an energy company focused on developing, constructing and operating wind and solar energy projects, either on its own or in partnership with other energy companies. The company's main focus is to seek out opportunities to utilize its technology to develop renewable energy sources.
Forward Looking Statements: This press release contains certain forward-looking statements. Investors are cautioned that certain statements in this release are "forward looking statements" and involve both known and unknown risks, uncertainties and other factors. Such uncertainties include, among others, certain risks associated with the operation of the company described above. The Company's actual results could differ materially from expected results.
The data collected will be used to refine the configuration in the internal chambers of the wind generator, thus making the unit as effective and efficient as possible.
Wind and solar are fast becoming the leading sources of renewable energy, which puts Kalahari Greentech in the right place at the right time. Kalahari Greentech designs, produces and provides wind turbines, solar collectors and other sustainable energy technologies. Nearly $2 billion in money from the American Recovery and Reinvestment Act has been spent on wind power, funding the creation of enough new wind farms to power 2.4 million homes over the past year. (Source: www.abcnews.com).
In a Bloomberg Business Week article, General Electric Co. said it expects global industry-wide sales for land-based wind turbines to grow by $130 billion in the next two years. (Source: http://www.businessweek.com/news/2010-03-02/ge-sees-130-bln-jump-in-land-turbine-sales-by-2012-update1-.html).
Kalahari's Wind Generator concentrates wind energy in a manner such that it can generate electric power at speeds usually too slow for conventional wind generators to produce any meaningful energy, or to even operate. It can also be modified to operate in water. For instance, it can be utilized in streams, rivers and tidal basins.
More information can be found on the company's website, www.kalaharigt.com.
About Kalahari Greentech, Inc.: Kalahari Greentech Inc. is an energy company focused on developing, constructing and operating wind and solar energy projects, either on its own or in partnership with other energy companies. The company's main focus is to seek out opportunities to utilize its technology to develop renewable energy sources.
Forward Looking Statements: This press release contains certain forward-looking statements. Investors are cautioned that certain statements in this release are "forward looking statements" and involve both known and unknown risks, uncertainties and other factors. Such uncertainties include, among others, certain risks associated with the operation of the company described above. The Company's actual results could differ materially from expected results.
mBeach Software Inc. ("MBHS") Presses for Progress on Russian and CIS Market Penetration
TEL AVIV, Israel, Sept. 27, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS - News): Following the August MOU with Russian company we are pressing for results from market penetration activities. To expedite the execution of mandatory procedures necessary for marketing approval in Russia, SCS, our wholly owned subsidiary, has forwarded all necessary information and technical support regarding SkinScan 650, our non-invasive, point-of-care system for the detection and identification of different types of skin cancers.
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. The health market opportunity is estimated at over $10 billion and forecast to grow at an impressive five-year compound average growth rate (CAGR) of 18.1% in US dollar terms.
According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
These activities follow mBeach's recent announcement on the signing of an MOU for Russia and the Commonwealth of Independent States (CIS).
Completing these regulatory procedures will pave the way for local clinical trials and a full commercial launch of SkinScan 650. We expect to receive the initial approval by the end of November 2010.
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Russia and the CIS are among the fastest-growing healthcare markets globally. Total population of the region exceeds 270 million people, and there is increasing demand for advanced medical technologies. The health market opportunity is estimated at over $10 billion and forecast to grow at an impressive five-year compound average growth rate (CAGR) of 18.1% in US dollar terms.
According to health care experts, one of the most serious problems with cancer treatment in Russia is a very low rate of early detection. Typically, the disease is diagnosed at very advanced stages when treatment options are less effective and more costly.
These activities follow mBeach's recent announcement on the signing of an MOU for Russia and the Commonwealth of Independent States (CIS).
Completing these regulatory procedures will pave the way for local clinical trials and a full commercial launch of SkinScan 650. We expect to receive the initial approval by the end of November 2010.
About SCS
Skin Cancer Scanning Ltd. (SCS) is a medical device company pioneering the development of a revolutionary and proprietary imaging system for the early detection and diagnosis of skin cancer.
Our product, SkinScan 650, is a non-invasive, point-of-care (in the doctor's office) system to detect and identify different kinds of skin nevi, tumors, lesions and cancers. SkinScan 650 enables physicians to diagnose skin cancer at an earlier, more curable stage. This will reduce the number of biopsies, lower treatment costs, and improve quality of life.
For more information on SCS, visit www.scs-med.com.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of SCS' products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
Genesis Electronics Bringing Reality to Technology From Johns Hopkins University Applied Physics Laboratory
HOLLYWOOD, FL--(Marketwire - 09/27/10) - Genesis Electronics Group, Inc. (OTC.BB:GEGI - News), www.genesiselectronicsgroup.com, a developer of solar-powered rechargeable battery modules for the Apple iPhone and iPod, the SunBlazer, is being showcased by Johns Hopkins University Applied Physics Laboratory (JHU/APL) in their upcoming INNOVATIONS Office of Technology Transfer Newsletter. The communication recognizes Genesis' creative use of their sophisticated technology and patent in the development of the solar powered product for consumers.
Below is the complete text of the newsletter from JHU/APL:
POWER PACKED
Infused with Johns Hopkins Applied Physics Laboratory Innovation, New Solar Charger Provides Energy on the Go
By Michael Buckley
In the mid-1990s, Johns Hopkins Applied Physics Laboratory researchers Joe Suter, Binh Le and Ark Lew had a clever idea for a small, thin, flexible device that can convert light to electricity.
They also had foresight and -- fortunately -- a bit of patience.
More than a decade later, their patented invention is close to reaching consumers. In late 2009, APL licensed the technology to Florida-based Genesis Electronics, which weaved APL's ideas into a sleek solar recharger called the SunBlazer's™. When attached to a cell phone or related electronic device, SunBlazer's™ 2- by 4-inch solar panel will continually draw energy from the Sun -- or any sufficient light source -- and keep the device charged.
"With its power and portability, the SunBlazer's™ is a true breakthrough in the recharging concept and an effective application of renewable energy," says Edward Dillon, CEO of Genesis Electronics Group.
Conceived primarily for use in satellites, APL's self-contained power circuit can fit a variety of applications and match the shape of the device it powers. Suter says that's why the inventors thought it also would have use in laptops or cell phones; yet they could only imagine the world of today, when practically everyone carries a cell phone, mobile computer or digital music player that all demand more and more power. "It was an invention before its time, before there was a market," Suter says. "So many people use these devices today, and they're looking for every bit of power they can find. The demand has caught up to our technology."
But Suter sees benefits beyond extra juice to run the latest apps and downloads. A quick jolt to a comatose phone battery might allow emergency calls from almost anywhere. Military readiness would get a boost from smaller, more efficient devices for powering GPS units, radios and countless other items soldiers carry that need a constant charge.
"APL researchers have the unique opportunity to deliver timely solutions to their sponsors and focus on the future applications of their technologies," says Kristin Gray, the Laboratory's Director of Technology Transfer. "In this case, they invented a solution to a problem that didn't even exist -- yet. That a technology devised in the 1990s could be relevant today tells you a lot about the insight and creativity that go into APL's cutting-edge work. And licensing these technologies to companies such as Genesis Electronics helps these innovative concepts to become reality."
Raymond F. Purdon, Genesis' Chairman of the Board, commented: "We are pleased to be working with Johns Hopkins University Applied Physics Laboratory and be in a position to apply their technology to the Genesis Electronics SunBlazer. There is a large demand for a cost effective solar powered battery charger for the iPhone and iPod. Genesis is intending to expand the relationship that we enjoy with JHU/APL for further research and development for future product development."
Genesis Electronics owns a solar-power source patent and has also secured the rights to two associated patents from Johns Hopkins University Applied Physics Laboratory.
For more information about the SunBlazer™ visit www.MySunblazer.com.
About Genesis Electronics, Inc.
Genesis Electronics, Inc. is a developmental stage electronics company with a patented process for charging and re-charging a battery from solar energy and efficiently transferring that energy to the battery of an electronic device. We have developed this technology to produce solar chargers for multi-featured cell phones, such as the G-2000 designed for the iPhone™. The key to Genesis Electronics' technology is its patented "Enhanced Solar to Battery Electronic Technology" for a unique process that charges a battery from solar energy and efficiently transfers that energy to the battery of an electronic device that optimizes the conversion of light into electrical energy. This technology can be applied to virtually any portable or hand-held electronic device.
Genesis Electronics, Inc. is a wholly-owned subsidiary of Genesis Electronics Group, Inc., a publicly traded corporation (symbol GEGI).
Forward Looking Statements
Except for historical matters, matters discussed in this release are forward-looking and are made pursuant to the safe harbor provisions of the 1995 Private Securities Litigation Reform Act. Investors are cautioned that these statements reflect numerous assumptions and involve risks and uncertainties that may affect Genesis Electronics Group, Inc., its business and prospects, and cause actual results to differ materially from these statements. Among these factors are Genesis Electronics Group, Inc.'s operations; competition; entry barriers; relationship reliance; technological changes; product demand; new systems introduction; vendors pricing; supply of software.
In light of risks and uncertainties in these forward-looking statements, they should not be regarded as a representation by Genesis Electronics Group, Inc. or any other person that the projected results, objectives or plans will be achieved. Genesis Electronics Group, Inc. undertakes no obligation to revise or update these statements to reflect events or circumstances after the date hereof.
Below is the complete text of the newsletter from JHU/APL:
POWER PACKED
Infused with Johns Hopkins Applied Physics Laboratory Innovation, New Solar Charger Provides Energy on the Go
By Michael Buckley
In the mid-1990s, Johns Hopkins Applied Physics Laboratory researchers Joe Suter, Binh Le and Ark Lew had a clever idea for a small, thin, flexible device that can convert light to electricity.
They also had foresight and -- fortunately -- a bit of patience.
More than a decade later, their patented invention is close to reaching consumers. In late 2009, APL licensed the technology to Florida-based Genesis Electronics, which weaved APL's ideas into a sleek solar recharger called the SunBlazer's™. When attached to a cell phone or related electronic device, SunBlazer's™ 2- by 4-inch solar panel will continually draw energy from the Sun -- or any sufficient light source -- and keep the device charged.
"With its power and portability, the SunBlazer's™ is a true breakthrough in the recharging concept and an effective application of renewable energy," says Edward Dillon, CEO of Genesis Electronics Group.
Conceived primarily for use in satellites, APL's self-contained power circuit can fit a variety of applications and match the shape of the device it powers. Suter says that's why the inventors thought it also would have use in laptops or cell phones; yet they could only imagine the world of today, when practically everyone carries a cell phone, mobile computer or digital music player that all demand more and more power. "It was an invention before its time, before there was a market," Suter says. "So many people use these devices today, and they're looking for every bit of power they can find. The demand has caught up to our technology."
But Suter sees benefits beyond extra juice to run the latest apps and downloads. A quick jolt to a comatose phone battery might allow emergency calls from almost anywhere. Military readiness would get a boost from smaller, more efficient devices for powering GPS units, radios and countless other items soldiers carry that need a constant charge.
"APL researchers have the unique opportunity to deliver timely solutions to their sponsors and focus on the future applications of their technologies," says Kristin Gray, the Laboratory's Director of Technology Transfer. "In this case, they invented a solution to a problem that didn't even exist -- yet. That a technology devised in the 1990s could be relevant today tells you a lot about the insight and creativity that go into APL's cutting-edge work. And licensing these technologies to companies such as Genesis Electronics helps these innovative concepts to become reality."
Raymond F. Purdon, Genesis' Chairman of the Board, commented: "We are pleased to be working with Johns Hopkins University Applied Physics Laboratory and be in a position to apply their technology to the Genesis Electronics SunBlazer. There is a large demand for a cost effective solar powered battery charger for the iPhone and iPod. Genesis is intending to expand the relationship that we enjoy with JHU/APL for further research and development for future product development."
Genesis Electronics owns a solar-power source patent and has also secured the rights to two associated patents from Johns Hopkins University Applied Physics Laboratory.
For more information about the SunBlazer™ visit www.MySunblazer.com.
About Genesis Electronics, Inc.
Genesis Electronics, Inc. is a developmental stage electronics company with a patented process for charging and re-charging a battery from solar energy and efficiently transferring that energy to the battery of an electronic device. We have developed this technology to produce solar chargers for multi-featured cell phones, such as the G-2000 designed for the iPhone™. The key to Genesis Electronics' technology is its patented "Enhanced Solar to Battery Electronic Technology" for a unique process that charges a battery from solar energy and efficiently transfers that energy to the battery of an electronic device that optimizes the conversion of light into electrical energy. This technology can be applied to virtually any portable or hand-held electronic device.
Genesis Electronics, Inc. is a wholly-owned subsidiary of Genesis Electronics Group, Inc., a publicly traded corporation (symbol GEGI).
Forward Looking Statements
Except for historical matters, matters discussed in this release are forward-looking and are made pursuant to the safe harbor provisions of the 1995 Private Securities Litigation Reform Act. Investors are cautioned that these statements reflect numerous assumptions and involve risks and uncertainties that may affect Genesis Electronics Group, Inc., its business and prospects, and cause actual results to differ materially from these statements. Among these factors are Genesis Electronics Group, Inc.'s operations; competition; entry barriers; relationship reliance; technological changes; product demand; new systems introduction; vendors pricing; supply of software.
In light of risks and uncertainties in these forward-looking statements, they should not be regarded as a representation by Genesis Electronics Group, Inc. or any other person that the projected results, objectives or plans will be achieved. Genesis Electronics Group, Inc. undertakes no obligation to revise or update these statements to reflect events or circumstances after the date hereof.
Thursday, September 23, 2010
U.S. Aerospace names Worsham CEO-industry sources
*Worsham is aerospace industry veteran
*Former CEO left as part of divestiture
WASHINGTON, Sept 23 (Reuters) - U.S. Aerospace Inc (USAE.OB), a Southern California-based aerospace contractor, has tapped industry veteran Jim Worsham as chief executive, industry sources said on Thursday.
Worsham, who previously held aerospace jobs with General Electric Co (GE.N) and the Douglas Aircraft unit of Boeing Co's (BA.N) McDonnell Douglas, has headed up aviation marketing and business development for the Southern California Logistics Airport for the last 10 years.
U.S. Aerospace announced earlier this month that its former chief executive, David Duquette, resigned that post as part of the divestiture of the company's machine-tool business [ID:nN15147827].
U.S. Aerospace attracted attention in July when it said it would partner with Antonov, the state-owned Ukrainian plane builder, to compete against Boeing and Airbus parent EADS (EAD.PA) for a multibillion-dollar contract to build a new generation of aerial refueling tankers for the U.S. military [ID:nN02192170].
In August, U.S. Aerospace filed a protest with the U.S. Government Accountability Office after its tanker proposal was rejected as late. (Reporting by Andrea Shalal-Esa, editing by Gerald E. McCormick)
*Former CEO left as part of divestiture
WASHINGTON, Sept 23 (Reuters) - U.S. Aerospace Inc (USAE.OB), a Southern California-based aerospace contractor, has tapped industry veteran Jim Worsham as chief executive, industry sources said on Thursday.
Worsham, who previously held aerospace jobs with General Electric Co (GE.N) and the Douglas Aircraft unit of Boeing Co's (BA.N) McDonnell Douglas, has headed up aviation marketing and business development for the Southern California Logistics Airport for the last 10 years.
U.S. Aerospace announced earlier this month that its former chief executive, David Duquette, resigned that post as part of the divestiture of the company's machine-tool business [ID:nN15147827].
U.S. Aerospace attracted attention in July when it said it would partner with Antonov, the state-owned Ukrainian plane builder, to compete against Boeing and Airbus parent EADS (EAD.PA) for a multibillion-dollar contract to build a new generation of aerial refueling tankers for the U.S. military [ID:nN02192170].
In August, U.S. Aerospace filed a protest with the U.S. Government Accountability Office after its tanker proposal was rejected as late. (Reporting by Andrea Shalal-Esa, editing by Gerald E. McCormick)
Subscribe to:
Posts (Atom)